Aclaris Therapeutics, Inc. (ACRS) vs MiniMed Group, Inc. (MMEDV)

A side-by-side comparison of Aclaris Therapeutics, Inc. and MiniMed Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ACRS

Aclaris Therapeutics, Inc.

$549M

$3.93HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

MMEDV

MiniMed Group, Inc.

$560M

$20.00HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ACRS vs MMEDV

growth of $100 · dividends reinvested · last 1y

ACRS -2.7% (-2.7%/yr)MMEDV +7.0% (+7.0%/yr)MMEDV compounded faster over this window

ACRS MMEDV

Metrics side by side

Total return (annualized)

Metric	ACRS	MMEDV
Total return (1Y)	128.66%	N/A
Total return CAGR (3Y)	-10.32%	N/A
Total return CAGR (5Y)	-24.23%	N/A
Total return CAGR (10Y)	-16.23%	N/A

MMEDV is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ACRS analysis Full MMEDV analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.